• Most Popular
  • Most Shared

Japan clears Herceptin for breast cancer: Roche

ZURICH
Fri Feb 29, 2008 1:58am EST

ZURICH (Reuters) - Japan's health authorities have approved Roche's cancer drug Herceptin for the treatment of HER2-positive breast cancer, the Swiss drugmaker said on Friday.

Health

HER2-positive breast cancer affects approximately 20 to 30 percent of women with breast cancer, the most common cancer among women worldwide, Roche said.

Each year more than 1 million new cases of breast cancer are diagnosed worldwide, and nearly 400,000 people will die of the disease annually, the firm said.

Herceptin, a humanized antibody, designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential, is marketed by Roche's subsidiary Chugai Pharmaceuticals in Japan.

(Reporting by Sven Egenter; Editing by Erica Billingham)
Health


More from Reuters

Photo

U.S. retailers open past midnight in holiday push

NEW YORK (Reuters) - In the nights before Christmas, some U.S. retailers are opening their doors round the clock to wring out every last possible holiday sale. | Video

» More Top News
A glass of water taken from a residential well after the start of natural gas drilling in Dimock, Pennsylvania, March 7, 2009. Dimock is one of hundreds of sites in Pennsylvania where energy companies are now racing to tap the massive Marcellus Shale natural gas formation. REUTERS/Tim Shaffer

Not in my watershed: NYC

The biggest U.S. city wants the state to ban one of the most promising sources of U.S. energy -- and also one of the most contentious.  Full Article 

Green Business
Cannabis sativa plant is seen in Buenos Aires, August 21, 2009. REUTERS/Enrique Marcarian
Bernd Debusmann:

Obama, drugs, common sense

American attitudes towards drug prohibition – and above all, punitive laws on marijuana – are changing too fast for policymakers and legislators to ignore.  Commentary 

U.S.